Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Recruiting
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (ICHD 2018). Migraine can be further categorized according to the frequency of attacks as episodic migraine (EM) or chronic migraine (CM). This study will assess the effects of BOTOX in preventing migraine in adult participants with EM. BOTOX is being developed for the prevention of migraine in adults with episodic migraine (EM). Participants w... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/06/2023
Locations: Accellacare /ID# 231496, Ames, Iowa
Conditions: Episodic Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
11/29/2023
Locations: Accellacare /ID# 229789, Ames, Iowa
Conditions: Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
11/27/2023
Locations: Meridian Clinical Research, LLC, Sioux City, Iowa
Conditions: Pediatric Migraine
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
Recruiting
Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
11/17/2023
Locations: Mercy One Iowa Heart Center, West Des Moines, Iowa
Conditions: Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Recruiting
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2023
Locations: Meridian Clinical Research, LLC, Sioux City, Iowa
Conditions: Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
10/18/2023
Locations: Integrated Clinical Trial Services, Inc., West Des Moines, Iowa
Conditions: Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
10/18/2023
Locations: Integrated Clinical Trial Services, Inc., West Des Moines, Iowa
Conditions: Migraine
Objectively Diagnose and Monitor Treatment of Light Sensitivity
Recruiting
The purpose of this project is to provide a new framework for diagnosing and monitoring treatment of light sensitivity and headache by objective measurement of facial features, pupil responses, retinal electrical responses and autonomic nerve responses to light.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
09/14/2023
Locations: University of Iowa Health Care, Iowa City, Iowa
Conditions: Photophobia, Traumatic Brain Injury, Migraine